Literature DB >> 21713389

Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF.

Mareike Ströfer1, Wolfgang Jelkmann, Reinhard Depping.   

Abstract

BACKGROUND: Curcumin, a commonly used spice, affects the activities of cytokines, enzymes, and transcription factors that are linked to inflammation. Furthermore, curcumin has been assigned tumor growth inhibiting effects, possibly mediated by promoting hypoxia-inducible factor (HIF) degradation. HIFs are transcription factors that play a central role in the adaptation and response to low oxygen levels in metazoan cells. However, curcumin also exhibits properties of an iron chelator indicating its potential of inhibiting HIF-α prolyl hydroxylase (PHD) activity.
METHODS: We were interested in clarifying these divergent actions of curcumin in due consideration of the effects on radio-therapy. Thus, concentration- and time-dependent effects of curcumin on HIF-α and -β protein levels and activity in hepatoma and breast carcinoma cell cultures under normoxic and hypoxic conditions were studied.
RESULTS: It was shown that HIF-1α accumulated in normoxia after the application of higher doses of the drug. Curcumin proved to lower HIF-1α and HIF-2α protein levels in hypoxia. HIF-1β (ARNT; arylhydrocarbon nuclear translocator) protein levels and HIF transcriptional activity were reduced in normoxia and hypoxia after 4 h and 24 h incubation periods. Furthermore, curcumin treatment negatively impacted on clonogenic cell survival of Hep3B hepatoma and MCF-7 breast carcinoma cells.
CONCLUSION: Effects of curcumin on cell growth and survival factor expression suggest its potential benefit in the treatment of cancer without a direct radiosensitizing influence of curcumin on these cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713389     DOI: 10.1007/s00066-011-2248-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  33 in total

Review 1.  Intensity-modulated radiation therapy (IMRT) with different combinations of treatment-planning systems and linacs: issues and how to detect them.

Authors:  Barbara Dobler; Friedlieb Lorenz; Hansjörg Wertz; Martin Polednik; Dirk Wolff; Volker Steil; Frank Lohr; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2006-08       Impact factor: 3.621

2.  Volumetric modulated arc therapy: IMRT in a single gantry arc.

Authors:  Karl Otto
Journal:  Med Phys       Date:  2008-01       Impact factor: 4.071

3.  Quasi-IMAT study with conventional equipment to show high plan quality with a single gantry arc.

Authors:  Judith Alvarez Moret; Oliver Kölbl; Ludwig Bogner
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

4.  Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors.

Authors:  Katja Freundt; Thekla Meyners; Amira Bajrovic; Hiba Basic; Johann H Karstens; Irenaeus A Adamietz; Volker Rudat; Steven E Schild; Juergen Dunst; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

5.  Volumetric arc intensity-modulated therapy for spine body radiotherapy: comparison with static intensity-modulated treatment.

Authors:  Q Jackie Wu; Sua Yoo; John P Kirkpatrick; Danthai Thongphiew; Fang-Fang Yin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-03       Impact factor: 7.038

6.  Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.

Authors:  Damien C Weber; Nicolas Peguret; Giovanna Dipasquale; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-01       Impact factor: 7.038

7.  Prognostic factors and a scoring system for patients with skeletal metastasis.

Authors:  H Katagiri; M Takahashi; K Wakai; H Sugiura; T Kataoka; K Nakanishi
Journal:  J Bone Joint Surg Br       Date:  2005-05

Review 8.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

Review 9.  Loss of biological effect in prolonged fraction delivery.

Authors:  Jack F Fowler; James S Welsh; Steven P Howard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

10.  Comparison of two commercial detector arrays for IMRT quality assurance.

Authors:  Jonathan G Li; Guanghua Yan; Chihray Liu
Journal:  J Appl Clin Med Phys       Date:  2009-04-29       Impact factor: 2.102

View more
  20 in total

1.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

2.  Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line.

Authors:  Rongrong Zhu; Xianzheng Wu; Yu Xiao; Bo Gao; Qian Xie; Hui Liu; Shilong Wang
Journal:  Cancer Biother Radiopharm       Date:  2013-06-29       Impact factor: 3.099

Review 3.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

4.  Effects of three modifiers of glycolysis on ATP, lactate, hypoxia, and growth in human tumor cell lines in vivo.

Authors:  A Yaromina; S Meyer; C Fabian; K Zaleska; U G A Sattler; L A Kunz-Schughart; W Mueller-Klieser; D Zips; M Baumann
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

5.  Dichloroacetate induces tumor-specific radiosensitivity in vitro but attenuates radiation-induced tumor growth delay in vivo.

Authors:  F Zwicker; A Kirsner; P Peschke; F Roeder; J Debus; P E Huber; K J Weber
Journal:  Strahlenther Onkol       Date:  2013-06-23       Impact factor: 3.621

6.  Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase.

Authors:  Huijin Fan; Weixi Tian; Xiaofeng Ma
Journal:  Target Oncol       Date:  2013-07-03       Impact factor: 4.493

Review 7.  Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo.

Authors:  Youcai Tang
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

8.  Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.

Authors:  Riyaz Basha; Sarah F Connelly; Umesh T Sankpal; Ganji Purnachandra Nagaraju; Hassaan Patel; Jamboor K Vishwanatha; Sagar Shelake; Leslie Tabor-Simecka; Mamoru Shoji; Jerry W Simecka; Bassel El-Rayes
Journal:  J Nutr Biochem       Date:  2016-02-10       Impact factor: 6.048

Review 9.  Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Roy A Jensen; Shrikant Anant
Journal:  Semin Cancer Biol       Date:  2016-09-05       Impact factor: 15.707

10.  Attenuation of oxidative stress, neuroinflammation, and apoptosis by curcumin prevents cognitive deficits in rats postnatally exposed to ethanol.

Authors:  Vinod Tiwari; Kanwaljit Chopra
Journal:  Psychopharmacology (Berl)       Date:  2012-07-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.